- Microbot Medical (MBOT, Financial) to present at first Endovascular Robotics session at SRS annual meeting on July 19, 2025.
- LIBERTY® Endovascular Robotic System is awaiting FDA 510(k) clearance, expected this quarter.
- The company is bolstering its US sales and marketing infrastructure for a potential LIBERTY launch.
Microbot Medical Inc. (MBOT), a pioneer in endovascular robotic technologies, is set to open the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting from July 16-20, 2025, in Strasbourg, France. The session, themed "Endovascular Robotics; the next frontier for robotic surgery," will be held on July 19 at 1:30am CEST. It will be moderated by Dr. Adnan Siddiqui from the University of Buffalo and Dr. Ryan Madder from Corewell Health.
CEO Harel Gadot will deliver an overview of the endovascular robotic market and introduce the company's LIBERTY® Endovascular Robotic System, which is currently an investigational device pending FDA 510(k) clearance, anticipated this quarter. The session aims to explore developments in peripheral vascular, neurovascular, and cardiovascular robotic technologies.
Microbot Medical is actively strengthening its sales and marketing infrastructure in preparation for the LIBERTY system's potential launch in the United States. The SRS meeting serves as a platform for the company to educate Interventional Radiologists and the broader medical community about their innovative endovascular robotic solutions. Microbot Medical's efforts reflect the increasing demand and technological advancements in the endovascular space.
